• 한국식품영양과학회지
• /
• 제29권1호
• /
• pp.128-133
• /
• 2000

This study was designed to verify the efficacy of garlic extracts for protecting the infecton of influenza and Japanese B encephalitis virus. Influenza virus (AO/PR8 strain) and Japanese B encephalitis virus (JaGAr O1 strain) were used to attack mouse through nasal route and each vaccines were injected subcutaneously. 0.002 and 0.2 mL/day of garlic extracts were orally administered to mice. The blood and serum samples were taken from the mice to measure LD50, Defense Index (DI), virus-neutralizing antibody for comparing virus influence inhibiting activities. Defense indices of the male and female mice were not significantly different at every experiment. Vaccination effectively inhibited the influence of influenza virus and 0.002 mL/day garlic extract (0.55$\pm$0.05) resulted in significantly higher DI than the control (0$\pm$0.05) (p<0.05). Although 0.002 mL/day garlic extract (0.55$\pm$0.05) resulted in significantly lower DI than the vaccination (1.10$\pm$0.05), 0.2 mL/day garlic extract (2.05$\pm$0.05) resulted in 10 times higher DI than the vaccination (1.10$\pm$0.05). Garlic extract did not affect DI in Japanese B encephalitis virus influence of the vaccinated mouse, but significantly reduced DI of the non-vaccinated mouse (p<0.05). Garlic extracts did not affect the production of the neutralizing antibody against influenza by vaccination. However, neutralizing antibody production of Japanese B encephalitis was accelerated by vaccination. Consequently, the current study proved the efficacy of garlic on inhibition of influenza virus. Finally, it is very hard to show the higher preventing effect on flu through ingestion of garlic as a food than vaccination.

• Journal of Microbiology and Biotechnology
• /
• 제14권1호
• /
• pp.121-127
• /
• 2004

Amphotericin B (AmB), an amphipathic polyene macrolide, is an antifungal drug produced by Streptomyces nodosus. Recently, AmB has been shown to exert antiviral activity against rubella virus and human immunodeficiency virus by different mechanisms. In this study, we evaluated the antiviral effect of AmB against Japanese encephalitis virus (JEV) and investigated which step of the viral life cycle was inhibited by AmB to understand the mechanism of antiviral action of AmB. AmB reduced both plaque size and number in the infected cells in a dose-dependent manner. In addition, a 200-fold reduction of infectious virus titer was observed by treatment of infected cells with $5\mug/ml$ of AmB. AmB acted at the post virus-infection step, but not during adsorption of virus to host cells. Western blot analysis revealed that the accumulated level of JEV envelope protein dramatically decreased in the infected cells by treatment with $5-10\mug/ml$ of AmB. Our results indicate that AmB inhibits the replication of JEV at the postinfection step by interfering with viral replication and/or by inhibiting the synthesis of viral proteins.

• 대한수의학회지
• /
• 제62권3호
• /
• pp.19.1-19.6
• /
• 2022

Japanese encephalitis virus (JEV) and Akabane virus (AKAV) are mosquito-borne viruses that cause encephalitis and reproductive disorders in horses and cattle, respectively. There is no treatment for JEV or AKAV infections in animals. Therefore, we evaluated the antiviral activity of 18-mer amphipathic peptides in the 1b-4/21-C series on JEV and AKAV using Vero cells in vitro and evaluated their effects on JEV in mice. Of 6 peptides, 1b-4/21-C12 had the lowest IC₅₀ of 0.313 against JEV and its use as an antiviral against JEV and AKAV was examined. The IC₅₀ of 1b-4/21-C12 against JEV and AKAV was 0.78 and 1.14 µM, respectively. Mice treated with 5 or 2 mg/kg of 1b-4/21-C12 had 32% and 16% survival rates, respectively, and the surviving mice treated with 1b-4/21-C12 began to gain weight beginning 8 days post challenge with the virulent Nakayama strain. Moreover, 20 µM 1b-4/21-C peptide had no cytotoxic effects on Vero cells. Our in vitro and in vivo results indicate that 1b-4/21-C12 has antiviral activity against enveloped JEV and AKAV and might be useful as a therapeutic substance.

• Annals of Clinical Neurophysiology
• /
• 제16권1호
• /
• pp.35-38
• /
• 2014

Japanese-B viral encephalitis (JE) usually has a monophasic illness pattern. A 45-year-old woman in an altered mentality had improved over 1 month. About 1 week after the initial improvement, the patient became comatose with aggravated EEG and MRI findings. Assays of cerebrospinal fluid and serum were positive for the IgM antibody to Japanese-B virus. After intravenous immunoglobulin (IVIG) infusion, the patient recovered. We report a patient with JE who showed a biphasic illness pattern and recovered after IVIG therapy.

• Journal of Microbiology and Biotechnology
• /
• 제32권9호
• /
• pp.1120-1125
• /
• 2022

Japanese encephalitis virus (JEV), the causative agent of Japanese encephalitis (JE), is an importantly zoonotic, vector-borne virus widely prevalent in Asia. Although JE has been well controlled in China, its prevalence remains a huge threat to the pig industry as well as human health. Herein, we report on our molecular and serological investigations of JEV among pigs from different regions in Hunan Province of China from 2019 to 2021. Collectively, 19.27% (583/3026, 95% Confidential Interval (CI) 17.86-20.68) of sampled pigs were positive for JEV IgG antibody as revealed by indirect enzyme-linked immunosorbent assay, and the seroprevalence of JEV among pigs was significantly associated with the development stage and breeding scale (p < 0.01). Meanwhile, 10.99% (42/382, 95% CI 7.86-14.13) of tissue samples of pigs with suspected clinical symptoms of JE and 23.44% (15/64, 95% CI 13.06-33.82) of mosquito batches were JEV-positive via reverse polymerase chain reaction. In addition, the complete E gene sequences of 14 JEV strains identified in this study were amplified and sequenced. Phylogenetic analysis showed that all 14 JEV strains belonged to genotype I-b and displayed a distinct genetic relationship to the present JEV vaccine strain (SA14-14-2). In conclusion, our results revealed not only the severe prevalence of JEV in Hunan Province, but also that JEV I-b might be the predominant genotype in Hunan Province, suggesting therefore that effective measures for JE control are urgently needed.

• 대한미생물학회지
• /
• 제1권1호
• /
• pp.3-3
• /
• 1958

• 대한수의학회지
• /
• 제11권2호
• /
• pp.163-170
• /
• 1971

Since the report in 1946 on the first isolation of Japanese encephalitis virus in Korea, the disease is known to occur every year and has occasionally spread in epidemic proportion among human populations. Because of its public health importance, it was deemed highly desirable to gain specific information as to natural history of the disease in Korea if we are to accomplish our ultimate objective of controling the disease in Korea. There still remain, however, unknown factors as to the ecology of Japanese encephalitis virus in Korea. This paper presents the results of serologic study on Korean cattle, hog and horse by means of hemagglutination inhibition (H.I.) test. The serum specimens were collected from Korean cattle, hog and horse their estimated ages being 3 to 9 years, 6 to 24 months and 2 to 14 years respectively, by jugular puncture; in Seoul and Kyung-Ki are a from the first part of May to November last, 1968. The strain used was designated by M 5/596. The methods of H.I. test employed in this study were essentially simillar to those employed by Clark and Fred. The results obtained summarized as follows; 1. Of samples of cattle sera tested, 183 (98%) was found to be positive, H.I. antibodies showing the highest proportion, on September. The lowest proportion showed 81 (68%) of 117 samples, on June. 2. One hundred and ninety-five and 114 swine serum samples tested were all of positive in both on September and October respectively. The lowest proportion showed 92 (29%) of 314 on June too. 3. Ninety (99%) of 91 equine serum samples tested contained demonstrable H.I. antibodies the highest proportion, on August. The lowest proportion was 19 (27%) of 70 samples on June. 4. Implications of these findings in the ecology of Japanese encephalitis Seoul and Kyung-Ki area were discussed.

• 대한수의학회지
• /
• 제32권3호
• /
• pp.365-368
• /
• 1992

1988년부터 1990년 6월까지 전국의 양돈장에서 수집된 돼지 유사산 태아 74복에서 바이러스성 원인체 분리 및 혈청학적 진단을 수행하였던 바 다음과 같은 결과를 얻었다. 공시한 74복의 유사산 태아중 44복의 태아 흉강액에서 면역 globulin이 검출되어 전염성 질병감염에 의한 유사산으로 추정되었다. 이중 37%가 바이러스성 유사산으로 나타났으며 유사산의 원인체별 분포를 살펴보면 돼지 파보바이러스가 21%로 가장 높았으며, 뇌심근염 바이러스가 11%, 일본뇌염 바이러스가 9% 등의 순으로 나타났다. 한편 돼지 콜레라바이러스 및 오제스키병 바이러스에 의한 유사산이 각각 1건씩 검출되었으며 동일 유사산 태아에서 2가지 병원체가 중복감염된 예도 관찰되었다.

• Pediatric Infection and Vaccine
• /
• 제15권1호
• /
• pp.1-4
• /
• 2008

Immunizations are among the most cost-effective and widely used public health interventions. This is a report a revision of recommendation of immunization for children by Korean Pediatric Society. Immunization. Vaccines were divided into 4 groups. 1) Vaccines that are recommended to all infants and children (BCG, hepatitis B vaccine, DTaP, Td, Polio vaccine, Japanese encephalitis vaccine, MMR, varicella vaccine, influenza vaccine [6-23 months of age], H. influenzae type b vaccine), 2) those that can be administered to all infants and children, but decision of administration is made by parents (pneumococcal conjugate vaccine, hepatitis A vaccine, influenza vaccine [healthy children ${\geq}24$ months of age], rotavirus vaccine, human papilloma virus vaccine), 3) those that should be given to high risk group (pneumococcal polysaccharide vaccine [high risk patients ${\geq}24$ months of age], influenza vaccine [high risk patients ${\geq}24$ months of age], typhoid vaccine), and 4) those administered for control of outbreaks or prevention of emerging infectious diseases. Immunization schedule recommended by Korean Pediatric Society in 2008 is presented.

• 한국동물위생학회지
• /
• 제24권4호
• /
• pp.359-367
• /
• 2001

A serological survey was performed to establish basic data for the prevalence of antibodies to some major diseases of domesticated boar serum samples from January to December 2000. Sera collected in breeding farms in Gyeongbuk province were tested for Aujeszky's disease virus(ADV), Porcine reproductive and respiratory syndrome virus(PRRSV), Porcine parvovirus(PPV), Japanese encephalitis virus (JEV), Bordetella bronchiseptica(B bronchiseptica), Mycoplasma ; APP), Toxoplasma, and Brucella. There was no antibody to ADV in domesticated boars serum samples detected by Anti-ADV-gpI assay kit. Sero-positive samples to PRRS by IFA were 0.9%(3/330) The HI titers to PPV ranged variously from less than 10 to over 1,280. Two hundred ninety-four out of 330 tested sera showed HI titer of less than 10. In HI test to JEV, 90.3% of the sera (298/330) were below 10. The majority of the serum samples had low prevalence of the antibody B bronchiseptica. ELISA titers to M hyopneumoniae ranged variously from $\leq$ 10 to $\geq$ 1,280. Antibody titers to A pleuropneumoniae type 2(APP2) and type 5(APP5) were 58.2% and 52.7%, respectively, and the tested samples showing ELISA antibody titers of less than 20. There was no significant geographical difference between APP2 and APP5 in this study. In the antibody test of Toxoplasma, 11.5%(38/330) were positive and samples were all negative in sera test of Brucella.